In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.

Visit link:
Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

Scroll to Top